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http://dx.doiabstractBACKGROUND: Tuberous sclerosis complex is a genetic disorder affecting every organ system, but disease manifes-
tations vary signiﬁcantly among affected individuals. The diverse and varied presentations and progression can be
life-threateningwith signiﬁcant impacton cost andqualityof life. Current surveillance andmanagementpractices are
highly variable among region and country, reﬂective of the fact that last consensus recommendations occurred in
1998 and an updated, comprehensive standard is lacking that incorporates the latest scientiﬁc evidence and current
best clinical practices.METHODS: The 2012 International Tuberous Sclerosis Complex Consensus Group, comprising
79 specialists from 14 countries, was organized into 12 separate subcommittees, each led by a clinician with
advanced expertise in tuberous sclerosis complex and the relevant medical subspecialty. Each subcommittee
focused on a speciﬁc disease area with important clinical management implications and was charged with
formulating key clinical questions to address within its focus area, reviewing relevant literature, evaluating the
strength of data, and providing a recommendation accordingly. RESULTS: The updated consensus recommendations
for clinical surveillance and management in tuberous sclerosis complex are summarized here. The recommen-
dations are relevant to the entire lifespan of the patient, from infancy to adulthood, including both individuals
where the diagnosis is newly made as well as individuals where the diagnosis already is established. CONCLUSIONS:
The 2012 International Tuberous Sclerosis Complex Consensus Recommendations provide an evidence-based,
standardized approach for optimal clinical care provided for individuals with tuberous sclerosis complex.
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Introduction
The clinical manifestations of tuberous sclerosis complex
(TSC) are highly diverse in both organ system involvementory:
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Open access under CC BYand severity. Any organ system can be involved, with some
more prevalent during infancy and childhood and others
more likely to affect individuals as adults.1 Birth incidence is
estimated to be 1:5800.2 Many manifestations can be life-
threatening and appropriate surveillance and manage-
ment is necessary to limit morbidity and mortality in this
disease. Appropriate management is also crucial for optimal
quality of life of affected individuals and requires coordi-
nation of care among medical specialties and from child-
hood to adulthood on a regular basis and especially during
the critical transition from pediatric to adult health care
services.
In 1998, the National Institutes of Health sponsored
the ﬁrst Tuberous Sclerosis Complex Consensus Confer-
ence to develop recommendations for diagnosis and
clinical management of patients affected by TSC.3,4 At-NC-ND license. 
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cases had been identiﬁed but their function and molec-
ular role were not yet known.5,6 We now know that the
TSC1 and TSC2 genes encode for hamartin (TSC1) and
tuberin (TSC2), which form a regulatory complex
responsible for limiting the activity of an important
intracellular regulator of cell growth and metabolism
known as mammalian target of rapamycin complex 1
(mTORC1) via inhibition of the small GTPase ras homolog
enriched in brain (Rheb).7 The functional relationship
between TSC1/TSC2 and mTORC1 has led to important
clinical advances in the use of mTORC1 inhibitors for the
treatment of several clinical manifestations of TSC,
including cerebral subependymal giant cell astrocy-
toma,8-11 renal angiomyolipomas,8,12,13 and pulmonary
lymphangioleiomyomatosis (LAM).8,13-15 Signiﬁcant ad-
vances in imaging, surgery, interventional radiology,
medical, and behavioral therapies have transformed TSC
management since 1998.
The extent of medical advances in TSC and the need to
standardize and optimize clinical care for individuals with
TSC necessitated updating the diagnostic criteria and
clinical management guidelines from 1998. In 2011, the
International Tuberous Sclerosis Complex Consensus Con-
ference was organized and sponsored by the Tuberous
Sclerosis Alliance, a nonproﬁt patient advocacy group and
member of Tuberous Sclerosis Complex International
(TSCi). Identiﬁcation of disease focus areas, participating
clinical expert contributors, clinical questions to address,
literature review process, and draft recommendations fol-
lowed. On June 14-15, 2012, 79 experts from 14 countries
convened in Washington, DC, to ﬁnalize diagnostic, sur-
veillance, and management recommendations for patients
with TSC. Finishing work and editing continued into early
2013. A summary report of revised diagnostic criteria for
TSC is provided separately.16 Here we summarize the
updated surveillance and management recommendations
for the standardized, optimal clinical management of pa-
tients with TSC.
Methods
Twelve subcommittees, each led by a clinician with advanced
expertise in TSC and the relevant medical subspecialty, were organized
to focus on speciﬁc disease focus topics that have important clinical
management implications in TSC: (1) dermatology and dentistry; (2)
nephrology; (3) pulmonology; (4) cardiology; (5) ophthalmology; (6)
gastroenterology; (7) endocrinology; (8) genetics; (9) epilepsy; (10)
TSC-associated neuropsychiatric disorders; (11) brain structure, tubers,
and tumors; and (12) coordination of clinical care. Each subcommittee
was charged with formulating key clinical questions to address within
its focus area, reviewing relevant literature, evaluating the strength of
data, and providing a recommendation based on evaluated literature
or, if data were lacking, an expert opinion based on experience or case
studies or other appropriate method. If no recommendation could be
provided because there was no consensus or conﬂicting evidence was
found of equal value or weight, the subcommittee was to provide
recommendations for future research that would help resolve the
conﬂict.
A centralized literature search was performed on March 12, 2012, for
all consensus group subcommittees to use. This search used PUBMED
and SCOPUS databases of all articles published between 1997 (year
before last consensus conference) and 2012 (current), regardless of
language. Search terms for PUBMED consisted of “tuberous sclerosis”
and “humans” and “diagnosis OR therapy.” Search terms for SCOPUSconsisted of “tuberous sclerosis” and “diagnosis OR treatment.” A total of
2692 articles were identiﬁed with this approach. Each consensus group
subcommittee was then able to determine additional terms pertinent to
its organ system or disease focus area to further reﬁne articles to be
reviewed and evaluated. Additional literature searches, if deemed
necessary by individual subcommittees to address key clinical questions
not captured by the central literature search, could be performed as
needed (e.g., epilepsy surgery or organ transplantation guidelines rele-
vant but not speciﬁc to TSC).
The evidence-based framework based on the approach of the Na-
tional Comprehensive Cancer Network (NCCN) Clinical Guidelines17 was
used to grade strength of evidence and resulting recommendations. The
NCCN framework allows recommendations based on all classes of evi-
dence by categorizing recommendations with regard to the type and
strength of evidence used to support the recommendation and is well-
suited for application across many organ systems and specialties for a
rare disease such as TSC with multisystem involvement. NCCN Clinical
Guidelines category 1 recommendations are based on high-level
evidence and uniform consensus, whereas category 2 recommenda-
tions are based on lower-level evidence and either uniform consensus or
consensus. Category 3 recommendations are those for which a
consensus cannot be reached, regardless of evidence. Additional details
regarding this framework, including deﬁnitions for high- and low-level
evidence, are provided in Table 1.
For the purposes of this summary document, the 2012 International
Tuberous Sclerosis Complex Consensus Group surveillance and man-
agement recommendations are organized into two sections: (1) rec-
ommendations applicable at the time of initial diagnosis and (2)
recommendations applicable to follow-up health care. There is some
overlap with this approach because some features discovered upon
initial diagnosis may require immediate intervention, additional
workup, or specialist referral. By necessity, discussion in this summary is
limited to the most relevant and salient points. More detailed discussion
of speciﬁc recommendations for the different TSC disease focus areas,
supporting evidence thereof, and other special considerations will be
published separately by each International Tuberous Sclerosis Consensus
Complex Group subcommittee.
Surveillance and management recommendations for
individuals with newly suspected or newly diagnosed TSC
TSC is usually ﬁrst suspected in individuals when one or
more clinical diagnostic criteria are identiﬁed (Table 2). The
purposes of initial diagnostic studies are to conﬁrm the
diagnosis in individuals with “possible” TSC and to deter-
mine the extent of disease and organ involvement in in-
dividuals with “deﬁnite” TSC. Baseline studies are also
important in guiding treatment decisions should additional
disease manifestations emerge in later years.
Genetics
All individuals should have a three-generation family
history obtained to determine if additional family members
are at risk of diagnosis. Gene testing is recommended for
genetic counseling purposes or when the diagnosis of TSC is
suspected or in question but cannot be clinically conﬁrmed
(Category 1).
Brain
All individuals suspected of having TSC, regardless of age,
should undergo magnetic resonance imaging (MRI) of the
brain with and without gadolinium to assess for the pres-
ence of cortical/subcortical tubers, subependymal nodules
(SEN), other types of neuronal migration defects, and sub-
ependymal giant cell astrocytomas (SEGA). If MRI is not
TABLE 1.
Recommendation categories and descriptions
Category Description Supporting Evidence
1 Based upon high-level evidence, there is uniform consensus
that the intervention is appropriate
At least one convincing class I study
OR
at least two convincing and consistent class II studies
OR
at least three convincing and consistent class III studies
2A Based upon lower-level evidence, there is uniform consensus
that the intervention is appropriate
At least one convincing class II study
OR
at least two convincing and consistent class III studies
2B Based upon lower-level evidence, there is consensus that the
intervention is appropriate
At least one convincing class III study
OR
at least two convincing and consistent class IV studies
3 Based upon any level of evidence, a consensus on appropriate
intervention cannot be reached
Class I-IV studies that are conﬂicting or inadequate to
form a consensus
Class Deﬁnitions for Supporting Evidence
Class I: evidence provided by a prospective, randomized, controlled clinical trial with masked outcome assessment, in a representative population.
Class II: evidence provided by a prospective matched group cohort study in a representative population with masked outcome assessment.
Class III: evidence provided by all other controlled trials (including well-deﬁned natural history controls or patients serving as own controls) in
a representative population, where outcome assessment is independent of patient treatment.
Class IV: evidence provided by uncontrolled studies, case series, case reports, or expert opinion.
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(CT) or head ultrasound (US) (in neonates or infants when
fontanels are open) may be used, although results are
considered suboptimal and will not always be able to detect
abnormalities revealed by MRI.18,19 (Category 1)
During infancy, focal seizures and infantile spasms (IS)
are likely to be encountered,20,21 and parents should be
educated to recognize these even if none have occurred at
time of ﬁrst diagnosis. All pediatric patients should undergo
a baseline electroencephalograph (EEG), even in the
absence of recognized or reported clinical seizures. (Cate-
gory 2A)
If the baseline EEG is abnormal, especially when features
of TSC-associated neuropsychiatric disorders (TAND) are
also present, this should be followed up with a 24-hourTABLE 2.
Surveillance and management recommendations for newly diagnosed or suspected tube
Organ System or
Specialty Area
Recommendation
Genetics  Obtain three-generation family history to assess for addi
 Offer genetic testing for family counseling or when TSC d
Brain  Perform magnetic resonance imaging (MRI) of the brain
defects, and subependymal giant cell astrocytoma (SEGA
 Evaluate for TSC-associated neuropsychiatric disorder (T
 During infancy, educate parents to recognize infantile sp
 Obtain baseline routine electroencephalogram (EEG). If a
video EEG to assess for subclinical seizure activity
Kidney  Obtain MRI of the abdomen to assess for the presence of
 Screen for hypertension by obtaining an accurate blood p
 Evaluate renal function by determination of glomerular ﬁ
Lung  Perform baseline pulmonary function testing (pulmonary
tomography (HRCT), even if asymptomatic, in patients at
or older. Adult males, if symptomatic, should also under
 Provide counsel on smoking risks and estrogen use in ad
Skin  Perform a detailed clinical dermatologic inspection/exam
Teeth  Perform a detailed clinical dental inspection/exam
Heart  Consider fetal echocardiography to detect individuals wi
via prenatal ultrasound
 Obtain an echocardiogram in pediatric patients, especial
 Obtain an electrocardiogram (ECG) in all ages to assess f
Eye  Perform a complete ophthalmologic evaluation, includinvideo EEG to assess for electrographic or subtle clinical
seizure activity. (Category 3)
TAND is new terminology proposed to describe the
interrelated functional and clinical manifestations of brain
dysfunction common in TSC, including aggressive behav-
iors, autism spectrum disorders, intellectual disabilities,
psychiatric disorders, and neuropsychological deﬁcits as
well school and occupational difﬁculties.22 All patients
should receive a comprehensive assessment at diagnosis to
determine a baseline for future evaluations and to identify
areas requiring immediate or early intervention. Compre-
hensive assessment is likely to require multidisciplinary
involvement and clinical teams should maintain a low
threshold to initiate early interventions and other man-
agement strategies. (Category 1)rous sclerosis complex (TSC)
tional family members at risk of TSC
iagnosis is in question but cannot be clinically conﬁrmed
to assess for the presence of tubers, subependymal nodules (SEN), migrational
)
AND)
asms, even if none have occurred at time of ﬁrst diagnosis
bnormal, especially if features of TAND are also present, follow-up with a 24-hr
angiomyolipoma and renal cysts
ressure
ltration rate (GFR)
function testing and 6-minute walk test) and high-resolution chest computed
risk of developing lymphangioleiomyomatosis (LAM), typically females 18 years
go testing
olescent and adult females
th high risk of heart failure after delivery when rhabdomyomas are identiﬁed
ly if younger than 3 yr of age
or underlying conduction defects
g dilated funduscopy, to assess for retinal lesions and visual ﬁeld deﬁcits
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individual education plan (IEP) based on the individual
TAND proﬁle. (Category 2A)Kidney
At the time of diagnosis, abdominal imaging should be
obtained regardless of age. As for brain, MRI is the preferred
modality for evaluation of angiomyolipomata becausemany
can be fat-poor and hencemissed when abdominal CT or US
are performed.23 MRI of the abdomen may be combined in
the same session as MRI of the brain, thereby limiting the
need for multiple sessions of anesthesia if anesthesia is
needed for successful MRI. MRI of the abdomen may also
reveal aortic aneurysms or extrarenal hamartomas of the
liver, pancreas, and other abdominal organs that also can
occur in individuals with TSC. In addition to imaging, ac-
curate blood pressure assessment is important because of
increased risk of secondary hypertension. To assess renal
function at time of diagnosis, blood tests to determine
glomerular ﬁltration rate (GFR) using creatinine equations
for adults24,25 or children.26 Alternatively, measurement of
serum cystatin C concentration can be used to evaluate
GFR.27 (Category 1)Lung
Toevaluate for LAM, females 18 years orolder shouldhave
baseline pulmonary function testing, 6-minute walk test,
and high-resolution chest computed tomography (HRCT).
When possible, low-radiation protocols should be used. A
serum vascular endothelial growth factor type D (VEGF-D)
level may be helpful to establish a baseline for future LAM
development or progression.28,29 Counseling on smoking
risks and estrogen use (such as some oral contraceptive
preparations), which can compound the impact of LAM,
should also occur in adolescents and adults. (Category 2A)Skin and teeth
All patients should undergo a detailed clinical dermato-
logic and dental exam at time of diagnosis to evaluate for
facial angioﬁbromas, ﬁbrous cephalic plaques, hypo-
melanotic macules or confetti lesions, ungual ﬁbromas,
shagreen patch, defects in tooth enamel, and intraoral ﬁ-
broma. (Category 2A)Heart
In pediatric patients, especially younger than three years
of age, an echocardiogram and electrocardiogram (ECG)
should be obtained to evaluate for rhabdomyomas and
arrhythmia, respectively. In those individuals with rhab-
domyomas identiﬁed via prenatal ultrasound, fetal echo-
cardiogram may be useful to detect those individuals with
high risk of heart failure after delivery. (Category 1)
In the absence of cardiac symptoms or concerning
medical history, echocardiogram is not necessary in adults,
but as conduction defects may still be present and may
inﬂuence medication choice and dosing,30 a baseline ECG is
still recommended. (Category 2A)Eye
A baseline ophthalmologic evaluation, including fundu-
scopic evaluation, is recommended for all individuals
diagnosed with TSC to evaluate for hamartomas and
hypopigmented lesions of the retina. (Category 1)
Other
Although vascular aneurysms, gastrointestinal polyps,
bone cysts, and various endocrinopathies can be associated
with TSC, there is insufﬁcient evidence to support routine
evaluation at time of diagnosis unless there are clinical
symptoms or other concerning history that warrants spe-
ciﬁc investigation. (Category 3)
Ongoing surveillance and management recommendations for
individuals previously diagnosed with TSC
Once the diagnosis of TSC is established and initial
diagnostic evaluations completed, continued surveillance is
necessary to monitor progression of known problems or
lesions and emergence of new ones (Table 3).20 Some
manifestations begin in childhood and are less likely to be
present or cause new problems in adulthood, such as car-
diac rhabdomyomas or subependymal giant cell astrocy-
tomas. In contrast, problems with LAM are typically limited
to adults, and renal manifestations require signiﬁcantly
more monitoring and intervention in adulthood compared
with childhood because of the cumulative nature of
angiomyolipomata and other renal lesions. Finally, other
aspects of TSC may be present throughout the entire life-
span of the individual, such as epilepsy and TAND, but
speciﬁc manifestations and impact on overall health and
quality of life can vary. Thus, ongoing periodic surveillance
is needed after initial diagnosis for optimal care and pre-
vention of secondary complications associated with TSC.
Management of speciﬁc complications of TSC will often
require input from a multidisciplinary team.
Genetics
Genetic testing and counseling should be offered to in-
dividuals with TSC when they reach reproductive age, and
ﬁrst-degree relatives of affected individuals should be
offered clinical assessment and, where a mutation has been
identiﬁed in the index case, genetic testing. (Category 1)
Brain
Symptomatic SEGA or SEGA associated with increasing
ventricular enlargement, or with unexplained changes in
neurological status or TAND symptoms, require interven-
tion or more frequent clinical monitoring and reimaging.
For acutely symptomatic individuals, surgical resection is
the recommended intervention, and cerebrospinal ﬂuid
diversion may also be necessary. For growing but otherwise
asymptomatic SEGA, either surgical resection or medical
therapy with mTOR inhibitors can be effective.31,32 Shared
decision-making with the patients or their parents in
selecting the best treatment option should take the
following considerations into account: risk of complications
or adverse effects, cost of treatment, expected length of
TABLE 3.
Surveillance and management recommendations for patients already diagnosed with deﬁnite or possible tuberous sclerosis complex (TSC)
Organ System or
Specialty Area
Recommendation
Genetics  Offer genetic testing and family counseling, if not done previously, in individuals of reproductive age or newly considering having children
Brain  Obtain magnetic resonance imaging (MRI) of the brain every 1-3 yr in asymptomatic TSC patients younger than age 25 yr to monitor for
new occurrence of subependymal giant cell astrocytoma (SEGA). Patients with large or growing SEGA, or with SEGA causing ventricular
enlargement but yet are still asymptomatic, should undergo MRI scans more frequently and the patients and their families should be educated
regarding the potential of new symptoms. Patients with asymptomatic SEGA in childhood should continue to be imaged periodically as adults
to ensure there is no growth.
 Surgical resection should be performed for acutely symptomatic SEGA. Cerebral spinal ﬂuid diversion (shunt) may also be necessary. Either
surgical resection or medical treatment with mammalian target of rapamycin complex (mTOR) inhibitors may be used for growing but
otherwise asymptomatic SEGA. In determining the best treatment option, discussion of the complication risks, adverse effects, cost, length
of treatment, and potential impact on TSC-associated comorbidities should be included in the decision-making process.
 Perform screening for TSC-associated neuropsychiatric disorders (TAND) features at least annually at each clinical visit. Perform comprehensive
formal evaluation for TAND at key developmental time points: infancy (0-3 yr), preschool (3-6 yr), pre-middle school (6-9 yr), adolescence
(12-16 yr), early adulthood (18-25 yr), and as needed thereafter. Management strategies should be based on the TAND proﬁle of each patient
and should be based on evidence-based good practice guidelines/practice parameters for individual disorders (e.g., autism spectrum disorder,
attention deﬁcit hyperactivity disorder, anxiety disorder). Always consider the need for an individual educational program (IEP). Sudden
change in behavior should prompt medical/clinical evaluation to look at potential medical causes (e.g., SEGA, seizures, renal disease).
 Obtain routine electroencephalograph (EEG) in individuals with known or suspected seizure activity. The frequency of routine EEG should be
determined by clinical need rather than a speciﬁc deﬁned interval. Prolonged video EEG, 24 hr or longer, is appropriate when seizure
occurrence is unclear or when unexplained sleep, behavioral changes, or other alteration in cognitive or neurological function is present
 Vigabatrin is the recommended ﬁrst-line therapy for infantile spasms. Adrenocorticotropin hormone (ACTH) can be used if treatment with
vigabatrin is unsuccessful. Anticonvulsant therapy of other seizure types in TSC should generally follow that of other epilepsies. Epilepsy
surgery should be considered for medically refractory TSC patients, but special consideration should be given to children at younger ages
experiencing neurological regression and is best if performed at epilepsy centers with experience and expertise in TSC.
Kidney  Obtain MRI of the abdomen to assess for the progression of angiomyolipoma and renal cystic disease every 1-3 yr throughout the lifetime of the
patient.
 Assess renal function (including determination of glomerular ﬁltration rate [GFR]) and blood pressure at least annually.
 Embolization followed by corticosteroids is ﬁrst-line therapy for angiomyolipoma presenting with acute hemorrhage. Nephrectomy is to be
avoided. For asymptomatic, growing angiomyolipoma measuring larger than 3 cm in diameter, treatment with an mTOR inhibitor is the
recommended ﬁrst-line therapy. Selective embolization or kidney-sparing resection are acceptable second-line therapy for asymptomatic
angiomyolipoma.
Lung  Perform clinical screening for lymphangioleiomyomatosis (LAM) symptoms, including exertional dyspnea and shortness of breath, at each
clinic visit. Counseling regarding smoking risk and estrogen use should be reviewed at each clinic visit for individuals at risk of LAM.
 Obtain high-resolution computed tomography (HRCT) every 5-10 yr in asymptomatic individuals at risk of LAM if there is no evidence of lung
cysts on their baseline HRCT. Individuals with lung cysts detected on HRCT should have annual pulmonary function testing (pulmonary
function testing and 6-min walk) and HRCT interval reduced to every 2-3 yr.
 mTOR inhibitors may be used to treat LAM patients with moderate to severe lung disease or rapid progression. TSC patients with LAM are
candidates for lung transplantation but TSC comorbidities may impact transplant suitability.
Skin  Perform a detailed clinical dermatologic inspection/exam annually.
 Rapidly changing, disﬁguring, or symptomatic TSC-associated skin lesions should be treated as appropriate for the lesion and clinical context,
using approaches such as surgical excision, laser(s), or possibly topical mTOR inhibitor.
Teeth  Perform a detailed clinical dental inspection/exam at minimum every 6 months and panoramic radiographs by age 7 yr, if not performed
previously.
 Symptomatic or deforming dental lesions, oral ﬁbromas, and bony jaw lesions should be treated with surgical excision or curettage when
present.
Heart  Obtain an echocardiogram every 1-3 yr in asymptomatic pediatric patients until regression of cardiac rhabdomyomas is documented. More
frequent or advanced diagnostic assessment may be required for symptomatic patients.
 Obtain electrocardiogram (ECG) every 3-5 yr in asymptomatic patients of all ages to monitor for conduction defects. More frequent or advanced
diagnostic assessment such as ambulatory and event monitoring may be required for symptomatic patients.
Eye  Perform annual ophthalmologic evaluation in patients with previously identiﬁed ophthalmologic lesions or vision symptoms at the baseline
evaluation. More frequent assessment, including those treated with vigabatrin, is of limited beneﬁt and not recommended unless new clinical
concerns arise.
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tients with unilateral, single, gross total resectable SEGA
without individual risk factors or other comorbidities
preferentially may beneﬁt from surgery, whereas patients
with multisystem disease or multiple or inﬁltrating SEGA
lesions that are not amenable to gross total resection may
favor mTOR inhibitor treatment. (Category 1)
Optimal outcome is associated with early detection and
treatment,33 so surveillance by MRI should be performed
every 1-3 years in all individuals with TSC until the age of
25 years. The frequency of scans within the recommended
range of every 1-3 years should be clinically determined,
with scans performed more frequently in those asymp-
tomatic SEGA patients who are younger, whose SEGA are
larger or growing, or who are developmentally orcognitively disabled such that they cannot reliably report
subtle symptoms. (Category 2A)
Individuals without SEGA by the age of 25 years do not
need continued surveillance imaging, but those with
asymptomatic SEGA present in childhood should continue to
be monitored by MRI for life because of the possibility of
growth. There is insufﬁcient evidence to determine the rec-
ommended frequencyofMRI surveillance in this latter group,
but important clinical factors that would favor shorter in-
tervals include SEGA with proximity to foramen of Monro,
large size, or recently discovered. However, once stability is
clearly established, itmay be possible to increase the interval
of surveillance monitoring over time. (Category 3)
Strong evidence demonstrates superior efﬁcacy for the
treatment of infantile spasms with vigabatrin in patients
D.A. Krueger, H. Northrup / Pediatric Neurology 49 (2013) 255e265260with TSC34e37; therefore, vigabatrin should be ﬁrst-line
treatment. However, the prescribing clinician should be
aware of possible side effects, particularly possible retinal
toxicity, and how to monitor for these. Adrenocorticotropin
hormone (ACTH) can be used as second-line therapy if
treatment with vigabatrin fails. (Category 1)
Routine EEG is recommended in individuals with known
or suspected seizure activity, but frequency should be
determined by clinical need rather than a speciﬁc deﬁned
interval. If changes in sleep, behavior, or cognitive or
neurological function are not explained by routine EEG, 24-
hour video EEG should be considered to assess for unrec-
ognized or subclinical seizure activity. (Category 2A)
Early epilepsy treatment may be of beneﬁt in infants and
children during the ﬁrst 24 months of life if ictal discharges
occur, with or without clinical manifestations.38 Other than
for infantile spasms in TSC, there is little evidence to guide
speciﬁc anticonvulsant treatment. In general, this should
follow that of other epilepsies, but it should be noted that
the prevalence of medically refractory epilepsy is high in
TSC even with adequate trials of currently available anti-
convulsant medications.30,39 Epilepsy surgery and vagus
nerve stimulation may be considered for medically re-
fractory TSC patients, but evaluation should take place at
epilepsy centers with experience and expertise in TSC, and
special consideration should be given to children at younger
ages experiencing neurological regression. (Category 2A)
Given that the physical features of TSC such as SEGA,
epilepsy, or renal failure may present with TAND-like be-
haviors, sudden and rapid changes in TAND should prompt
an urgent overall physical workup in such individuals.
(Category 1)
After detailed initial assessment upon diagnosis, it is
imperative to continue to monitor for features of TAND and
their impact on daily living through basic questioning and
screening procedures at each follow-up clinic visit, with a
minimum frequency of once per year. Any areas of concern
identiﬁed at routine TAND assessment should be followed
up with more detailed evaluations by the appropriate
developmental, neuropsychological, mental health, behav-
ioral, and educational specialists and coordinated by the
TSC expert team. (Category 1)
In addition to screening at each clinical visit, compre-
hensive, formal evaluations for TAND by an expert team
should be performed at key scheduled time points: during
the ﬁrst 3 years of life (0-3 year evaluation), preschool (3-6
year evaluation), before middle school entry (6-9 year
evaluation), during adolescence (12-16 year evaluation),
and in early adulthood (18-25 year evaluation). In later
adulthood, evaluations should be performed as clinical
challenges emerge or based on TAND screening. More
frequent specialty evaluations or treatment/interventions
may be needed if annual screening reveals areas of concern.
(Category 2A)
Several studies are under way to investigate the use of
mTOR inhibitors as treatment for aspects of TAND. To date
there is insufﬁcient evidence to support the use of mTOR
inhibitors as treatment for any aspects of TAND. There are
no other TSC-speciﬁc neuropsychiatric interventions to
date. However, there is high level evidence of treatment
strategies for individual disorders associated with TAND,
such as autism spectrum disorder, attention deﬁcithyperactivity disorder, and anxiety. Clinical teams should
therefore use evidence-based principles to guide thera-
peutic decisions for best treatment of TAND in individuals
with TSC, individualized to each patient. (Category 3)
Kidney
For asymptomatic, growing angiomyolipoma measuring
larger than 3 cm in diameter, treatment with an mTOR in-
hibitor is currently recommended as the most effective
ﬁrst-line therapy in the short term.8,13,14,40 The demon-
strated tolerability so far to date is far preferable to the renal
damage caused by angiomyolipoma progression as well as
surgical and embolitic/ablative therapies, though studies
are still needed to conﬁrm long-term beneﬁts and safety.
(Category 1)
Annual clinical assessment of renal function and hyper-
tension is required. Blood pressure control is also critical, so
accurate measurement of blood pressure for patients is
crucial, using age-speciﬁc criteria for children.41 Patients
with hypertension should be treatedwith an inhibitor of the
renin-aldosterone-angiotensin system as ﬁrst line therapy,
but avoiding an angiotensin-converting enzyme inhibitor in
those treated with an mTOR inhibitor. (Category 1)
Imaging to diagnose polycystic disease, renal cell carci-
noma or other tumors,42,43 and changes in angiomyolipoma
should also be performed. MRI, often obtainable at the same
time as brain surveillance imaging, is the preferred imaging
modality, but if MRI is not available, CTor US can still provide
useful information.44 Selective embolization followed by
corticosteroids,45 kidney-sparing resection, or ablative ther-
apy for exophytic lesions are acceptable second-line therapy
for asymptomatic angiomyolipomata. For acute hemorrhage,
embolization followed by corticosteroids is more appro-
priate.46 Nephrectomy is to be avoided because of the high
incidence of complications and increased risk of future renal
insufﬁciency, end-stage renal failure, and the poor prognosis
that results from chronic kidney disease.12,47 Fat-poor
angiomyolipomata are not uncommon in patients with TSC,
but if there is doubt and lesions are growing faster than
0.5 cmperyear,48 aneedlebiopsyusing a sheath techniqueor
an open biopsy may be considered. (Category 2A)
Lung
In individuals at risk for LAM, typically females 18 years
of age and older, history at each clinical examination should
inquire for symptoms of exertional dyspnea and shortness
of breath. In patients with no clinical symptoms and no
evidence of lung cysts on their baseline HRCT, repeat HRCT
imaging should be performed every 5-10 years, using low-
radiation imaging protocols when available. Once cysts are
detected, pace of TSC-LAM progression should be deter-
mined via HRCT testing every 2-3 years accompanied by
annual pulmonary function testing and 6-minute walk test.
If many cysts or other evidence of advanced TSC-LAM are
present, pulmonary function testing and HRCT may be
needed as frequently as every 3-6 months to assist with
treatment decision-making. (Category 1)
In select LAM patients with moderate-to-severe lung
disease or rapid progression, treatment with an mTOR in-
hibitor may be used to stabilize or improve pulmonary
D.A. Krueger, H. Northrup / Pediatric Neurology 49 (2013) 255e265 261function, quality of life, and functional performance.8,13e15
(Category 1)
TSC-LAM patients are candidates for lung trans-
plantation, but it is important to note that antirejection
medications may lower seizure threshold and seizure
medications may interfere with antirejection medications.
TSC comorbidities could also impact transplant suitability.
(Category 2A)
Skin and teeth
A skin survey should be performed annually, with focus
on rapidly changing or symptomatic (problematic or func-
tionally impacting) lesions and using pathological evalua-
tion when required for diagnosis. Early intervention is
indicated for bleeding, symptomatic, or potentially dis-
ﬁguring TSC skin lesions. There is insufﬁcient evidence to
guide choice of treatmentdcase reports and case series
document successful use of surgical excision, lasers, and
topical mTOR inhibitors.49-53 (Category 3)
For TSC-associated dental lesions and oral ﬁbromas, pe-
riodic oral evaluation should occur every 3-6 months,
consistent with surveillance recommendations for all in-
dividuals in the general population. Periodic preventive
measures as well as oral hygiene education are important in
patient management. Bony jaw lesions (asymmetry,
asymptomatic swelling, or abnormal tooth eruption), when
present, should be evaluated with a panoramic radiograph
and treated with surgical excision or curettage if symp-
tomatic or deforming.54 Enamel defects (dental pits) can be
treated with restorative treatments if the patient is at high
cavity risk, although they rarely cause symptoms or an
increased incidence of dental decay.55,56 Oral ﬁbromas
should be excised surgically if symptomatic or if interfering
with oral hygiene. Oral ﬁbromas may recur once excised;
therefore, periodic oral evaluation is encouraged.57 (Cate-
gory 3)
Heart
Until regression of cardiac rhabdomyomas is docu-
mented, follow-up echocardiogram should be performed
every 1-3 years in asymptomatic patients. In addition, 12-
lead ECG is recommended at minimum every 3-5 years to
monitor for conduction defects. In patients with clinical
symptoms, additional risk factors, or signiﬁcant abnormal-
ities on routine echocardiogram or ECG, more frequent in-
terval assessment may be needed and may include
ambulatory event monitoring. (Category 1)
Eye
Individuals with no identiﬁed ophthalmologic lesions or
vision symptoms at baseline, reevaluation is necessary only
if new clinical concerns arise. Otherwise, annual evaluation
is recommended. For patients on vigabatrin, ophthalmo-
logic evaluation every 3 months is recommended by the
United States Food and Drug Administration, although
utility of such frequent assessment is questioned, especially
in the young and those with developmental disability that
limit the extent of ophthalmologic evaluation that can be
performed.30,58 Thus, even in these populations, annualophthalmologic evaluation is considered more appropriate.
(Category 2B)
Other
There is limited, low-level evidence to guide recom-
mendations for gastrointestinal, endocrine, and other
hamartomatous lesions associated with TSC. Follow-up
imaging to ensure stability of these lesions, when present,
is recommended. Biopsy of suspicious lesions is recom-
mended only when lesions are unusually large, growing,
functional, symptomatic, multiple, or exhibit other suspi-
cious characteristics. (Category 3)
Coordination of care and other clinical considerations in
patients with TSC
TSC is a heterogeneous genetic disorder with variable
expression and thus its clinical presentations are protean.
The primary pathology of concern is also different
depending on the age of the affected individual. The
involvement of multiple organ systems, at different stages
in life, presents major difﬁculties in locating and identifying
the expertise to comprehensively manage the medical care
of individuals with TSC. The purpose of the 2012 Interna-
tional TSC Consensus Conference was to provide recom-
mendations that help standardize the approach to
managing TSC regardless of age or severity of the disease.
Currently in the United States and many other countries,
specialized TSC clinics have been established. Ideally, all TSC
patients would have access to these clinics to ensure the
appropriateness of care and treatment, but this ultimately
may not be possible. In circumstances in which individuals
with TSC do not have access to the specialized TSC clinics,
the recommendations from the TSC Consensus Conference
will be of signiﬁcant value. Another source of invaluable
information would be prominent advocacy groups such as
the Tuberous Sclerosis Alliance in the United States and
many similar groups in countries throughout theworldwho
are also members of Tuberous Sclerosis International.
Resources must be used efﬁciently, particularly when
there are ﬁnancial or technological limitations. Transition
clinics or clinics/facilities that treat both children and adults
with TSC are important, particularly for the more severely
affected and those with multiorgan system effects. Doing so
can avoid duplicative tests and services and ensure appro-
priate surveillance and symptommanagement is in place to
prevent more costly medical complications. TSC clinics may
be institution-based or community-based using a network
of clinicians expert in the different aspects of TSC. These
clinics must be able to address the psychosocial challenges
that face the individual and their family or caregivers as
well as the medical needs.
These diagnostic and surveillance recommendations
were developed from an ever-increasing understanding of
TSC and supported by published, scientiﬁc investigation.
Continued improvement in clinical knowledge will likely
come from planned and ongoing clinical trials investigating
a host of potential treatments for TSC, and also from lon-
gitudinal databases (e.g., the US TSC Natural History Data-
base, the TOSCA European TSC Registry), which will serve to
capture information on the many manifestations and
D.A. Krueger, H. Northrup / Pediatric Neurology 49 (2013) 255e265262treatments of TSC throughout the human life cycle. As
clinical knowledge of the disease improves, the current
recommendations will have to be updated periodically.
The 2012 International TSC Clinical Consensus Conference was sponsored and
organized by the Tuberous Sclerosis Alliance. The conference was supported by
generous sponsors who donated funds to the Tuberous Sclerosis Alliance without
playing a role in the planning or having a presence at the conference and the
resulting recommendations: the Rothberg Institute for Childhood Diseases, Novartis
Pharmaceuticals, Sandra and Brian O’Brien, and Questcor Pharmaceuticals.
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